Call for information/EOI for neutralising antibodies

Concepts

• pharmaceutical products
• dhsc
• antibodies
• therapeutics taskforce
• initial identification of potential therapeutics
• dhsc invites suppliers
• clinical trials
• end provision of treatments
• covid-19 infection
• effective treatments

Location

Description

DHSC invites suppliers to submit an EOI on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose&frequency, formats/routes for administering to patients, monitoring adverse affects, efficacy against SARSCoV- 2 variants, supply availability for 2021- 2022 and future years and plans for regulatory approval in the UK, if not yet approved. **Updated information on 9th December 2021** The Therapeutics Taskforce is responsible for the end-to-end provision of treatments for COVID-19 in the UK, from the initial identification of potential therapeutics, to trialing treatments as part of an advanced programme of clinical trials, and their eventual deployment at scale to the patient population. These safe and effective treatments are vital for lessening the severity and impact of COVID-19 in individuals and communities. The Taskforce is seeking to gather information in respect of neutralising antibodies that can be deployed in a hospital or community setting. Therapeutics suppliers must provide evidence of their therapies' potential efficacy and progress in trials, monitoring and safety. The market engagement will take the form of a webinar held on Thursday 16th December 2021.

CPV Codes

• 33600000 - Pharmaceutical products

Other Information

The webinar will take interested suppliers through the requirement outlined in this Prior Information Notice and will provide an opportunity for suppliers to ask questions. To sign up to join the webinar please visit: https://www.eventbrite.co.uk/e/prior-information-notice-antiviral-drug-supply-fo... We are inviting suppliers to register their interest in the PIN by downloading a questionnaire via the Atamis platform, and sending a completed version to http://health.atamis.co.uk by 13:00 on 23rd December 2021. Responses to this questionnaire will be kept in confidence and will inform the Taskforce's market research. Suppliers are not required to fill out a questionnaire before attending the webinar. Any information shared in the webinar will be shared with all suppliers via the Atamis platform after the market engagement period associated with this PIN closes on Thursday 23rd December 2021.